Day One Biopharmaceuticals (NASDAQ:DAWN) Issues Earnings Results

Day One Biopharmaceuticals (NASDAQ:DAWN) issued its earnings results on Tuesday. The company reported ($0.69) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by ($0.34), Zacks reports.

Day One Biopharmaceuticals Trading Down 3.0 %

Shares of NASDAQ:DAWN traded down $0.36 during trading on Tuesday, hitting $11.82. 1,383,849 shares of the company’s stock traded hands, compared to its average volume of 985,195. The company has a 50-day moving average price of $12.36 and a 200-day moving average price of $13.47. Day One Biopharmaceuticals has a 52 week low of $11.13 and a 52 week high of $18.07. The company has a market cap of $1.19 billion, a price-to-earnings ratio of -11.48 and a beta of -1.46.

Insider Buying and Selling

In other news, CEO Jeremy Bender sold 12,048 shares of the stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $11.96, for a total transaction of $144,094.08. Following the completion of the sale, the chief executive officer now owns 128,015 shares of the company’s stock, valued at $1,531,059.40. This represents a 8.60 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Charles N. York II sold 4,370 shares of the firm’s stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $11.96, for a total transaction of $52,265.20. Following the sale, the chief financial officer now owns 252,638 shares in the company, valued at approximately $3,021,550.48. The trade was a 1.70 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 51,064 shares of company stock valued at $651,225. 8.40% of the stock is owned by corporate insiders.

Analyst Ratings Changes

A number of equities analysts have issued reports on DAWN shares. Needham & Company LLC reaffirmed a “buy” rating and issued a $33.00 price objective on shares of Day One Biopharmaceuticals in a research note on Monday, January 13th. HC Wainwright restated a “buy” rating and issued a $40.00 price target on shares of Day One Biopharmaceuticals in a research report on Thursday, October 31st. TD Cowen upgraded Day One Biopharmaceuticals to a “strong-buy” rating in a report on Monday, November 4th. Bank of America cut their target price on Day One Biopharmaceuticals from $28.00 to $25.00 and set a “buy” rating on the stock in a research note on Tuesday, January 7th. Finally, The Goldman Sachs Group decreased their target price on Day One Biopharmaceuticals from $48.00 to $43.00 and set a “buy” rating for the company in a research report on Monday, February 10th. One investment analyst has rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average price target of $35.71.

Day One Biopharmaceuticals Company Profile

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.